Q-omics provides the consensus-scored RMND5B profile across patient tissues and cancer cell-line models. RMND5B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RMND5B is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, RMND5B RNA expression shows 19,949 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where RMND5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RMND5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RMND5B survival associations across molecular data types. RMND5B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RMND5B RNA expression–survival associations across cancer types. High RMND5B expression shows unfavorable associations in UVM, LIHC, KICH and LAML, but favorable associations in KIRC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RMND5B RNA expression.
This table summarizes RMND5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RMND5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RMND5B shows lower tumor expression in HNSC and LUSC and higher tumor expression in LIHC, BRCA, COAD and KIRP. The HNSC box plot shows higher RMND5B RNA expression in normal versus tumor tissue (log2 FC = −1.044, t-test p < 0.001).
This table shows molecular features associated with RMND5B in patient tissues and cancer cell lines. In patient samples, RMND5B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RMND5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
